179 related articles for article (PubMed ID: 35821652)
1. Serum cell-free DNA as a new biomarker in cutaneous T-cell lymphoma.
Mizuno Y; Shibata S; Miyagaki T; Ito Y; Taira H; Omori I; Hisamoto T; Oka K; Matsuda KM; Boki H; Takahashi-Shishido N; Sugaya M; Sato S
J Dermatol; 2022 Nov; 49(11):1124-1130. PubMed ID: 35821652
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
3. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma.
Vonderheid EC; Martinez AR
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):228-238.e4. PubMed ID: 30745139
[TBL] [Abstract][Full Text] [Related]
6. Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma.
Suga H; Sugaya M; Miyagaki T; Ohmatsu H; Fujita H; Kagami S; Asano Y; Tada Y; Kadono T; Sato S
Acta Derm Venereol; 2013 Mar; 93(2):144-9. PubMed ID: 22948508
[TBL] [Abstract][Full Text] [Related]
7. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
[TBL] [Abstract][Full Text] [Related]
8. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma.
Peru S; Prochazkova-Carlotti M; Cherrier F; Velazquez J; Richard E; Idrissi Y; Cappellen D; Azzi-Martin L; Pham-Ledard A; Beylot-Barry M; Merlio JP; Poglio S
J Invest Dermatol; 2022 Dec; 142(12):3243-3252.e10. PubMed ID: 35850209
[TBL] [Abstract][Full Text] [Related]
10. Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma.
Senda N; Miyagaki T; Kamijo H; Nakajima R; Oka T; Takahashi N; Suga H; Yoshizaki A; Asano Y; Sugaya M; Sato S
Eur J Dermatol; 2018 Oct; 28(5):621-627. PubMed ID: 30378541
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma.
Scarisbrick JJ; Whittaker S; Evans AV; Fraser-Andrews EA; Child FJ; Dean A; Russell-Jones R
Blood; 2001 Feb; 97(3):624-30. PubMed ID: 11157477
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous T-cell lymphoma. Refinement in the application of controversial histologic criteria.
Glusac EJ; Shapiro PE; McNiff JM
Dermatol Clin; 1999 Jul; 17(3):601-14, ix. PubMed ID: 10410861
[TBL] [Abstract][Full Text] [Related]
13. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract][Full Text] [Related]
14. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
[TBL] [Abstract][Full Text] [Related]
15. Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma.
Olsen EA
Dermatol Clin; 2015 Oct; 33(4):643-54. PubMed ID: 26433839
[TBL] [Abstract][Full Text] [Related]
16. Myocosis fungoides--an update on a non-mycotic disease.
Makdisi J; Friedman A
J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
[TBL] [Abstract][Full Text] [Related]
17. A modified staging classification for cutaneous T-cell lymphoma.
Kashani-Sabet M; McMillan A; Zackheim HS
J Am Acad Dermatol; 2001 Nov; 45(5):700-6. PubMed ID: 11606919
[TBL] [Abstract][Full Text] [Related]
18. Memorials and mandates for cutaneous lymphomas.
Heald PW
Arch Dermatol; 2003 Jul; 139(7):926-8. PubMed ID: 12873891
[No Abstract] [Full Text] [Related]
19. [Rare variants of cutaneous T-cell lymphomas].
Goerdt S; Trautmann C; Kütting B; Ramaker J; Schmuth M; Thiel E; Luger T; Stein H; Orfanos CE
Hautarzt; 1996 Feb; 47(2):96-105. PubMed ID: 8868452
[TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment in mycosis fungoides and Sézary syndrome.
Rubio Gonzalez B; Zain J; Rosen ST; Querfeld C
Curr Opin Oncol; 2016 Jan; 28(1):88-96. PubMed ID: 26632770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]